Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical r...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth
Format:	Artykuł
Język:	English
Wydane:	Frontiers Media S.A. 2023-04-01
Seria:	Frontiers in Immunology
Hasła przedmiotowe:	severe asthma remission clinical outcomes real-world eosinophil biology mepolizumab
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150162/full

Podobne zapisy

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab
od: Yuki Hirata, i wsp.
Wydane: (2022-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
od: Masanobu Ueno, i wsp.
Wydane: (2022-06-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
od: Mkorombindo T, i wsp.
Wydane: (2019-08-01)

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
od: Diego Bagnasco, i wsp.
Wydane: (2024-04-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
od: Steven W. Yancey, i wsp.
Wydane: (2019-09-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
od: Haldar P
Wydane: (2017-06-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
od: Nina B. Curkovic, MD, i wsp.
Wydane: (2024-11-01)

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
od: Masamitsu Hamakawa, i wsp.
Wydane: (2024-01-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
od: Masanobu Ueno, i wsp.
Wydane: (2021-03-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
od: Ryota Otoshi, i wsp.
Wydane: (2020-03-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
od: V. N. Drozdov, i wsp.
Wydane: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
od: Giuseppe A. Ramirez, i wsp.
Wydane: (2022-12-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
od: Pelaia C, i wsp.
Wydane: (2017-10-01)

May mepolizumab used in asthma correct subfertility?
od: Guzin Ozden, i wsp.
Wydane: (2021-01-01)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
od: Nobuhiro Matsumoto, i wsp.
Wydane: (2019-10-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
od: Venkata Nagarjuna Maturu, i wsp.
Wydane: (2021-08-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
od: Takanori Numata, i wsp.
Wydane: (2019-10-01)

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
od: Jolita Palacionyte, i wsp.
Wydane: (2024-06-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
od: Alistair Cook, i wsp.
Wydane: (2021-05-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
od: Takanori Numata, i wsp.
Wydane: (2020-01-01)

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
od: Kenneth R. Chapman, i wsp.
Wydane: (2024-02-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
od: I. J. Pouliquen, i wsp.
Wydane: (2017-11-01)

Mepolizumab para el tratamiento de asma grave eosinofílica
od: Armando Partida-Gaytán, i wsp.
Wydane: (2021-01-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
od: M. Sabbe, i wsp.
Wydane: (2024-01-01)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
od: Takashi Yamane, i wsp.
Wydane: (2023-06-01)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
od: Magdalena Żychowska, i wsp.
Wydane: (2020-06-01)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia [version 3; peer review: 2 approved]
od: Moetemri Zied, i wsp.
Wydane: (2023-09-01)

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia
od: Milos Jesenak, i wsp.
Wydane: (2023-09-01)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
od: Madeleine Lachance, MD, i wsp.
Wydane: (2022-04-01)

Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
od: Nana Ayame, i wsp.
Wydane: (2024-09-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
od: Yu‐Hsuan Chen, i wsp.
Wydane: (2022-01-01)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
od: Azmat Karim, i wsp.
Wydane: (2022-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
od: Carlo Lombardi, i wsp.
Wydane: (2024-07-01)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
od: Peter G. Gibson, i wsp.
Wydane: (2021-06-01)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
od: Takahiro Matsuyama, i wsp.
Wydane: (2023-06-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
od: Nami Masumoto, i wsp.
Wydane: (2023-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
od: N. M. Nenasheva
Wydane: (2018-10-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
od: Marco Caminati, i wsp.
Wydane: (2023-09-01)

Gastrointestinal Involvement of Eosinophilic Granulomatosis with Polyangiitis with Histological Evidence of Treatment Response
od: Mark Lai, i wsp.
Wydane: (2023-03-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
od: Manuel David Gil-Sierra, i wsp.
Wydane: (2019-11-01)